2020
The tumor immune microenvironment and its implications for clinical outcome in patients with oropharyngeal squamous cell carcinoma
GURÍN, Dominik; Marek SLÁVIK; Markéta HERMANOVÁ; Iveta SELINGEROVÁ; Tomáš KAZDA et. al.Základní údaje
Originální název
The tumor immune microenvironment and its implications for clinical outcome in patients with oropharyngeal squamous cell carcinoma
Autoři
GURÍN, Dominik; Marek SLÁVIK; Markéta HERMANOVÁ; Iveta SELINGEROVÁ; Tomáš KAZDA; Michal HENDRYCH; Tetiana SHATOKHINA a Marcela VESELÁ
Vydání
JOURNAL OF ORAL PATHOLOGY & MEDICINE, HOBOKEN, WILEY, 2020, 0904-2512
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30109 Pathology
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 4.253
Kód RIV
RIV/00216224:14110/20:00116131
Organizační jednotka
Lékařská fakulta
UT WoS
000544754600001
EID Scopus
2-s2.0-85087306024
Klíčová slova anglicky
CD8; HPV; oropharyngeal squamous cell carcinoma; PD-L1; tumor-infiltrating lymphocytes
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 29. 10. 2020 13:38, Mgr. Tereza Miškechová
Anotace
V originále
Background We examined PD-L1 expression on tumor cells (TCs) and immune cells (ICs) and density of CD3(+)and CD8(+)tumor-infiltrating lymphocytes (TILs) in patients with oropharyngeal squamous cell carcinoma (OPSCC) and investigated their significance on clinicopathological characteristics and clinical outcomes. Methods In a cohort of 65 patients treated by definitive intensity-modulated radiotherapy (IMRT) with curative intent, immunohistochemical analysis of PD-L1 expression on TCs and ICs, and TIL subtyping was performed on primary biopsy tumor tissues, followed by prognostic evaluation of these immune response-related parameters including classification into four tumor immune microenvironment (TIM) types. To evaluate HPV status, p16 immunohistochemistry was performed. Results Densities of CD3(+)and CD8(+)TILs and PD-L1 expressions on TCs and ICs were significantly higher in p16+/HPV-mediated OPSCC. Patients with high densities of stromal CD8(+)TILs displayed significantly better overall survival (OS) and progression-free survival (PFS). PD-L1 expression neither on tumor cells nor on immune cells affected survival outcomes. Distribution of TIM types based on the combination of PD-L1 expression on TCs and densities of CD8(+)TILs is significantly different in p16+ compared with p16- OPSCC. In type III TIM (TC-PD-L1+/low CD8(+)TIL density), significantly better OS was shown in p16+ group compared with p16- OPSCC. Conclusion The prognostic and predictive role of tumor immune microenvironment was confirmed for patients with OPSCC. Combining HPV status with the evaluation of densities of CD8(+)TILs and PD-L1 expression including TIM classification might be of high clinical interest and warrants further prospective evaluation.